APOB and metabolic dysfunction-associated steatohepatitis: Among patients with NASH (N = 20), mean (± SD) plasma apoB concentrations did not differ between baseline and week 12 of ACCi therapy (106 ± 8 vs. 106 ± 9 mg/dl, P = 0.9; Fig. 2A).